|
Markt geschlossen -
Euronext Bruxelles
17:55:00 05.10.2026
|
Perf. 5 T | Veränd. 1. Jan. | ||
| 200.90 EUR | -1.66% |
|
-5.46% | -15.80% |
| 30.09. | Experimentelles Medikament von Merck gegen Hauterkrankung erzielt Erfolg in Studie der mittleren Phase | RE |
| 30.09. | UCB präsentiert auf einem Kongress neue Daten zu Bimzelx |  |
ETFs investiert in UCB
| Name | % 1. Jan. | Gewichtung | Volumen | |
|---|---|---|---|---|
 | +7.03% | -.--% | 6 576 M€ | |
| +16.95% | -.--% | 750 M€ | |
| +10.74% | -.--% | 13 M€ | |
| +0.71% | -.--% | 51 M€ | |
| +10.59% | -.--% | 66 M€ | |
| +6.76% | -.--% | 75 M€ | |
| +15.33% | -.--% | 4 105 M€ | |
| +8.89% | -.--% | 274 M€ | |
| +16.69% | -.--% | 298 M€ | |
| +8.43% | -.--% | 6 M€ | |
| -.--% | -.--% | 1 683 M€ | |
| +13.79% | -.--% | 1 674 M€ | |
| +5.40% | -.--% | 1 193 M€ | |
| +9.39% | 13.82% | 85 M€ | |
| +3.61% | 9% | 162 M€ | |
| +20.64% | 4.37% | 49 M€ | |
| +0.57% | 4.19% | 94 M€ | |
| -3.60% | 2.41% | 391 M€ | |
| +21.73% | 2.2% | 1 260 M€ | |
| -3.55% | 1.85% | 1 024 M€ | |
| +3.53% | 1.85% | 9 M€ | |
| +1.87% | 1.79% | 25 M€ | |
| -5.32% | 1.75% | 820 M€ | |
| +8.58% | 1.69% | 31 M€ | |
| +11.73% | 1.69% | 31 M€ | |
| +8.64% | 1.49% | 18 M€ | |
| +9.11% | 1.45% | 490 M€ | |
| +8.79% | 1.45% | 3 283 M€ | |
| +10.98% | 1.34% | 160 M€ | |
| +2.71% | 1.3% | 64 M€ | |
| +14.81% | 1.28% | 173 M€ | |
| +13.03% | 1.19% | 757 M€ | |
| +8.04% | 1.18% | 17 M€ | |
| +13.39% | 1.17% | 13 M€ | |
| +3.11% | 1.13% | 22 M€ | |
| +7.54% | 1.13% | 16 M€ |
Beschäftigte
9’000
Sektor
Pharmazeutika
Termine
- Börse
- Aktien
- 852738 Aktie
- ETFs UCB
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
